Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Earnings
Rallybio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2025
$200.00K
-33.3% on a year earlier
EPS, Q3 FY2025
$0.36
-$0.26 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Rallybio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $200.00K | -33.3% | $0.36 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $200.00K | -33.3% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $200.00K | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 13, 2025before the open | $38.00K | – | -$0.25 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $300.00K | – | -$0.26 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $300.00K | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | – | – | -$0.47 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024before the open | – | – | -$0.50 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | – | – | -$0.45 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | – | – | -$0.46 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | – | – | -$0.43 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023before the open | – | – | -$0.46 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022before the open | – | – | -$0.60 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022before the open | – | – | -$0.57 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | – | – | -$0.48 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 15, 2022before the open | – | – | -$0.42 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | – | – | -$0.37 | Release |
| Q2 FY2021ended Jun 30, 2021 | Sep 9, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Rallybio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Rallybio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Rallybio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Update
- Update
- Results
- Results
- News
- Results
- News
- Results
- Results
- Results
See a number that looks wrong?